Two Sigma Advisers
PVLA

Two Sigma Advisers’s Palvella Therapeutics PVLA Stock Holding History

Two Sigma Advisers’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,300
Closed -$241K – 2284
2025
Q4 		$241K Buy
+2,300
New +$196K ﹤0.01% 2051
2024
Q2 		– Sell
-424
Closed -$6.21K – 2712
2024
Q1 		$6.21K Sell
424
-9
-2% -$125 ﹤0.01% 2423
2023
Q4 		$6.3K Buy
433
+128
+42% +$2.34K ﹤0.01% 2470
2023
Q3 		$7.27K Buy
305
+42
+16% +$903 ﹤0.01% 2352
2023
Q2 		$3.48K Sell
263
-30
-10% -$1.82K ﹤0.01% 2356
2023
Q1 		$22.8K Sell
293
-556
-65% -$64.4K ﹤0.01% 2510
2022
Q4 		$70.6K Sell
849
-285
-25% -$22.9K ﹤0.01% 2333
2022
Q3 		$104K Sell
1,134
-722
-39% -$93.1K ﹤0.01% 2305
2022
Q2 		$278K Sell
1,856
-3,257
-64% -$594K ﹤0.01% 2148
2022
Q1 		$1.24M Sell
5,113
-8,373
-62% -$2.2M ﹤0.01% 1521
2021
Q4 		$4.08M Sell
13,486
-448
-3% -$143K 0.01% 857
2021
Q3 		$5.76M Buy
+13,934
New +$4.85M 0.01% 718
2021
Q2 		– Sell
-345
Closed -$71K – 2736
2021
Q1 		$71K Sell
345
-156
-31% -$34.1K ﹤0.01% 2472
2020
Q4 		$100K Sell
501
-102
-17% -$21.2K ﹤0.01% 2270
2020
Q3 		$100K Sell
603
-801
-57% -$182K ﹤0.01% 2275
2020
Q2 		$348K Buy
1,404
+125
+10% +$29.2K ﹤0.01% 2053
2020
Q1 		$233K Sell
1,279
-74
-5% -$18.6K ﹤0.01% 2117
2019
Q4 		$392K Sell
1,353
-103
-7% -$28.6K ﹤0.01% 1969
2019
Q3 		$397K Sell
1,456
-44
-3% -$17K ﹤0.01% 1805
2019
Q2 		$564K Sell
1,500
-9
-0.6% -$2.69K ﹤0.01% 1765
2019
Q1 		$404K Sell
1,509
-17
-1% -$4.04K ﹤0.01% 1873
2018
Q4 		$325K Buy
1,526
+13
+0.9% +$4.03K ﹤0.01% 1954
2018
Q3 		$678K Buy
1,513
+40
+3% +$17.4K ﹤0.01% 1672
2018
Q2 		$597K Buy
1,473
+258
+21% +$123K ﹤0.01% 1852
2018
Q1 		$663K Buy
1,215
+728
+149% +$451K ﹤0.01% 1717
2017
Q4 		$294K Buy
+487
New +$226K ﹤0.01% 1951

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers's PVLA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 2,300 shares — an estimated $241K sold.

Two Sigma Advisers first reported a position in PVLA in Q4 2017 and held it in 26 quarters. The position peaked at $5.76M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 2,300 Palvella Therapeutics shares in Q1 2026, an estimated $241K.
  • Two Sigma Advisers first reported a position in Palvella Therapeutics in Q4 2017 and held it in 26 quarters.
  • Two Sigma Advisers's Palvella Therapeutics position peaked at $5.76M in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.